GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GT Biopharma GTBP · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.32

-2.26%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About GT Biopharma

From its filings with the US Securities and Exchange Commission

SEC filings

GT Biopharma is based in San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GTBP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2020, it reported revenue of $0.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
22 Oct 2013
Employees
2
Head office
505 MONTGOMERY STREET, SAN FRANCISCO, CA, 94111
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Michael BreenExecutive Chairman of the Board, Chief Executive Officer, since 2021$1.2m
  • Mr. Alan UrbanChief Financial Officer, Secretary, since 2022$377,782
  • Mr. Charles CasamentoIndependent Director$65,000
  • Ms. Hilary KramerIndependent Director
  • Mr. David Mun-GavinNon-Executive Independent Director
  • Mr. Corey DavisIR Contact Officer, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
17
Environment
19
Social
11
Governance
20
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • GT Biopharma's TriKE platform enhances natural killer cell cancer treatment capabilities.
  • GTB-3550 is a single-chain tri-specific recombinant fusion protein for CD33-expressing cancers.
  • The company focuses on immuno-oncology with a proprietary technology platform.

Weaknesses

  • The company employs only 2 full-time employees, limiting operational capacity.
  • Headquartered in Brisbane California, a location with limited biotech infrastructure.
  • The firm has no commercialized products yet, relying solely on clinical development.

Opportunities

  • Expanding TriKE platform applications to infectious disease treatments beyond cancer.
  • Phase 1 trial results for GTB-3550 could attract further investment and partnerships.
  • Growing immuno-oncology market in Health Care sector offers significant potential.

Threats

  • Competition from larger biotech firms with more resources in immuno-oncology.
  • Regulatory hurdles may delay clinical trials and product approvals.
  • Limited funding due to small employee count and early-stage development.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.